Antibody Immune Response Pharma Companies 
pharmaphorum
NOVEMBER 30, 2020
Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment. As AAV is a virus derived from the common cold, the immune system can easily have levels of pre-existing NAbs that will recognise and neutralise AAV, rendering it ineffective.
pharmaphorum
FEBRUARY 9, 2022
While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response. The promise of this approach means that there is now a growing pipeline of potential cancer vaccines emerging from within the portfolios of larger pharma companies and biotechs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 11, 2020
The test has been designed to quantitatively measure of immunoglobulin G (IgG) antibodies to aid clinicians in identifying patients with an immune Covid-19 response pre- and post-vaccination. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.
pharmaphorum
DECEMBER 21, 2020
It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at the end of the year. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2
pharmaphorum
JANUARY 7, 2021
The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients. Equally important to the company is the safety data gathered as the technology is used as the pharma companies use it to guide development of cancer immunotherapies.
pharmaphorum
FEBRUARY 14, 2022
Like Shingrix, CRV-101 is a subunit vaccine based on the glycoprotein E (gE) antigen of the herpes zoster virus, delivered alongside an adjuvant to boost the immune response. The post Vaccines upstart Curevo has designs on blockbuster GSK franchise appeared first on.
pharmaphorum
SEPTEMBER 20, 2022
Vaccines have transitioned from being a largely unloved area of the industry, with multiple big pharma companies divesting their vaccine divisions , to the biggest revenue drivers seen in recent years. Serum neutralising antibody increases were noted to be particularly high in subjects who had previously received an mRNA vaccine.
Expert insights. Personalized for you.
105 
Let's personalize your content